ETF Trends (Free subscription) | 05/10/2008
Biotechnology is rising up to analyst's predictions that a near future run could send related stocks and exchange traded funds (ETFs) up. The latest April announcement that Takeda Pharmaceutical would buy Massachusetts-based Millennium Pharmaceuticals (MLMN) for $8.8 billion sent the...
Market Wire - Investment Opinion (Free subscription) | 05/09/2008
LONDON (MARKET WIRE)
Seeking Alpha (Free subscription) | 05/09/2008
Don Dion submits: The April announcement that Japanese drug maker Takeda Pharmaceutical would buy Massachusetts-based Millennium Pharmaceuticals (MLNM) (which sells the anticancer injection Velcade) for $8.8 billion sent Millennium shares markedly higher. The acquisition also lifted expectations for a run of biotech M&A, boosting much of the sector. Complete Story ยป
The Earth Times Online Newspaper (Free subscription) | 05/09/2008
OSAKA, Japan, and CAMBRIDGE, Mass., May 9 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited, Takeda , and Millennium Pharmaceuticals, Inc., Millennium today announced the succe...
The Earth Times Online Newspaper (Free subscription) | 05/09/2008
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 7.7 percent fall in annual operating profit on Friday and forecast a sharp drop for the current year on costs for its $8.8 billion purchase of U.S. biotech firm Millennium Pharmaceuticals.
Reuters (Free subscription) | 05/09/2008
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 7.7 percent fall in annual operating profit on Friday and forecast a sharp drop for the current year on costs for its $8.8 billion purchase of U.S. biotech firm Millennium Pharmaceuticals.
Market Wire - Investment Opinion (Free subscription) | 05/06/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM), Gilead Sciences, Inc. (NASDAQ: GILD).
Patent Docs (Free subscription) | 05/03/2008
By Donald Zuhn -- In March, we reported on the lobbying expenditures for a number of biotech and pharmaceutical companies in 2007. For example, we noted that Millennium Pharmaceuticals had spent $1.28 million, Genentech $1.8 million, and AstraZeneca $4.1 million in 2007. Topping each of these companies, however, was Abbott...
The Boston Business Journal (Free subscription) | 04/29/2008
Government regulators in the United States, Austria and Germany have cleared the planned $8.8 billion sale of Millennium Pharmaceuticals Inc. to Japanese drug maker Takeda Pharmaceutical Co. Ltd.
Fiercebiotech (Free subscription) | 04/29/2008
Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Two weeks ago, Takeda helped seal Levin's reputation Read more...
Law Blog - WSJ.com (Free subscription) | 04/24/2008
Takeda's bid to buy Millennium Pharmaceuticals could weigh on profits and share prices in the short term. Still, analysts say the acquisition, which gives Takeda a foothold in the lucrative cancer-drug market and bolsters its pipeline, may be good news for investors in the long run.
Japan Times (Free subscription) | 04/18/2008
NEW YORK (Kyodo) A shareholder of U.S. biotechnology-based drugmaker Millennium Pharmaceuticals Inc. has sued the company over plans by Takeda Pharmaceutical Co. to conduct a tender offer for Millennium shares, a Millennium official said Wednesday.
mac.ro (Free subscription) | 04/14/2008
Zacks Equity Research highlights Millennium Pharmaceuticals (Nasdaq: MLNM) as the Bull of the Day and Arkansas Best Corporation (Nasdaq: ABFS) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Apple, Inc. (Nasdaq: AAPL), Johnson Controls (NYSE: JCI) and Telefonica (NYSE: TEF). Full analysis of all these stocks is available at [at.zacks.com]
mac.ro (Free subscription) | 04/14/2008
CHICAGO----Zacks Equity Research highlights Millennium Pharmaceuticals as the Bull of the Day and Arkansas Best Corporation as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Apple, Inc. , Johnson Controls and Telefonica .
MacMike News (Free subscription) | 04/14/2008
Zacks Equity Research highlights Millennium Pharmaceuticals (Nasdaq: MLNM) as the Bull of the Day and Arkansas Best Corporation (Nasdaq: ABFS) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Apple, Inc. (Nasdaq: AAPL), Johnson Controls (NYSE: JCI) and Telefonica (NYSE: TEF). Full analysis of all these stocks is available at [...]
